

Lung stain image

## An Eligibility Guide for KEYTRUDA

# A Key to Personalizing Treatment for Certain Patients: Biomarker Testing

KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with NSCLC expressing PD-L1 [tumor proportion score (TPS)  $\geq 1\%$ ] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is:

- stage III where patients are not candidates for surgical resection or definitive chemoradiation, or
- metastatic.

See additional indications inside.

NSCLC = non-small cell lung cancer; PD-L1 = programmed death ligand 1; EGFR = epidermal growth factor receptor; ALK = anaplastic lymphoma kinase.


## SELECTED SAFETY INFORMATION

### SUMMARY OF IMMUNE-MEDIATED REACTIONS

- Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue and can affect more than one body system simultaneously. Immune-mediated adverse reactions can occur at any time during or after treatment with KEYTRUDA, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatologic reactions, solid organ transplant rejection, other transplant (including corneal graft) rejection, and complications of allogeneic hematopoietic stem cell transplantation. Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions. Early identification and management of immune-mediated adverse reactions are essential to ensure safe use of KEYTRUDA. Based on the severity of the adverse reaction, KEYTRUDA should be withheld or permanently discontinued and corticosteroids administered if appropriate. For more information regarding immune-mediated adverse reactions, please read the additional Selected Safety Information on pages 2-7.




**Before prescribing KEYTRUDA, please read the additional Selected Safety Information on the following pages and the [Prescribing Information](#). The [Medication Guide](#) also is available.**





# KEYTRUDA Is Approved for a Range of Patients

Slide image is a copyright © of Agilent Technologies, Inc. 2023. Reproduced with Permission, Courtesy of Agilent Technologies, Inc.

Tumor Type	Indication	PD-L1 Testing	PD-L1 Result
 <b>Advanced NSCLC or Adjuvant Treatment for NSCLC</b>	KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.		
	KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC.		
	KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with NSCLC expressing PD-L1 (TPS $\geq 1\%$ ) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: <ul style="list-style-type: none"><li>stage III where patients are not candidates for surgical resection or definitive chemoradiation, or</li><li>metastatic.</li></ul>		<b>TPS <math>\geq 1\%</math></b>
	KEYTRUDA, as a single agent, is indicated for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS $\geq 1\%$ ) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.		<b>TPS <math>\geq 1\%</math></b>
	KEYTRUDA is indicated for the treatment of patients with resectable (tumors $\geq 4$ cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.		
	KEYTRUDA, as a single agent, is indicated as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with stage IB (T2a $\geq 4$ cm), II, or IIIA NSCLC.		

## SELECTED SAFETY INFORMATION


### Severe and Fatal Immune-Mediated Adverse Reactions

- KEYTRUDA is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death receptor-1 (PD-1) or the programmed death ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions. Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue, can affect more than one body system simultaneously, and can occur at any time after starting treatment or after discontinuation of treatment. Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.
- Monitor patients closely for symptoms and signs that may be clinical manifestations of underlying immune-mediated adverse reactions. Early identification and management are essential to ensure safe use of anti-PD-1/PD-L1 treatments. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. For patients with TNBC treated with KEYTRUDA in the neoadjuvant setting, monitor blood cortisol at baseline, prior to surgery, and as clinically indicated. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.
- Withhold or permanently discontinue KEYTRUDA depending on severity of the immune-mediated adverse reaction. In general, if KEYTRUDA requires interruption or discontinuation, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose adverse reactions are not controlled with corticosteroid therapy.

TNBC = triple-negative breast cancer.





Before prescribing KEYTRUDA, please read the additional Selected Safety Information on the previous and following pages, and the [Prescribing Information](#). The [Medication Guide](#) also is available.

**KEYTRUDA**<sup>®</sup>  
(pembrolizumab) Injection 100 mg



# KEYTRUDA Is Approved for a Range of Patients

Slide image is a copyright © of Agilent Technologies, Inc. 2023. Reproduced with Permission, Courtesy of Agilent Technologies, Inc.

Tumor Type	Indication	PD-L1 Testing	PD-L1 Result
 Advanced HNSCC	KEYTRUDA, in combination with platinum and fluorouracil (FU), is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC).		
	KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [combined positive score (CPS) $\geq 1$ ] as determined by an FDA-approved test.		<b>CPS <math>\geq 1</math></b>
	KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.		
 Advanced esophageal or GEJ carcinoma	KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy.		
	KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic esophageal or GEJ (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS $\geq 10$ ) as determined by an FDA-approved test.		<b>CPS <math>\geq 10</math></b>

## SELECTED SAFETY INFORMATION (*continued*)

### Severe and Fatal Immune-Mediated Adverse Reactions (*continued*)

#### Immune-Mediated Pneumonitis


- KEYTRUDA can cause immune-mediated pneumonitis. The incidence is higher in patients who have received prior thoracic radiation. Immune-mediated pneumonitis occurred in 3.4% (94/2799) of patients receiving KEYTRUDA, including fatal (0.1%), Grade 4 (0.3%), Grade 3 (0.9%), and Grade 2 (1.3%) reactions. Systemic corticosteroids were required in 67% (63/94) of patients. Pneumonitis led to permanent discontinuation of KEYTRUDA in 1.3% (36) and withholding in 0.9% (26) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, 23% had recurrence. Pneumonitis resolved in 59% of the 94 patients.
- Pneumonitis occurred in 7% (41/580) of adult patients with resected NSCLC who received KEYTRUDA as a single agent for adjuvant treatment of NSCLC, including fatal (0.2%), Grade 4 (0.3%), and Grade 3 (1%) adverse reactions. Patients received high-dose corticosteroids for a median duration of 10 days (range: 1 day to 2.3 months). Pneumonitis led to discontinuation of KEYTRUDA in 26 (4.5%) of patients. Of the patients who developed pneumonitis, 54% interrupted KEYTRUDA, 63% discontinued KEYTRUDA, and 71% had resolution.

#### Immune-Mediated Colitis

- KEYTRUDA can cause immune-mediated colitis, which may present with diarrhea. Cytomegalovirus infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies. Immune-mediated colitis occurred in 1.7% (48/2799) of patients receiving KEYTRUDA, including Grade 4 (<0.1%), Grade 3 (1.1%), and Grade 2 (0.4%) reactions. Systemic corticosteroids were required in 69% (33/48); additional immunosuppressant therapy was required in 4.2% of patients. Colitis led to permanent discontinuation of KEYTRUDA in 0.5% (15) and withholding in 0.5% (13) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, 23% had recurrence. Colitis resolved in 85% of the 48 patients.



Before prescribing KEYTRUDA, please read the additional Selected Safety Information on the previous and following pages, and the [Prescribing Information](#). The [Medication Guide](#) also is available.

**KEYTRUDA**<sup>®</sup>  
(pembrolizumab) Injection 100 mg



# KEYTRUDA Is Approved for a Range of Patients

Slide image is a copyright © of Agilent Technologies, Inc. 2023. Reproduced with Permission, Courtesy of Agilent Technologies, Inc.

Tumor Type	Indication	PD-L1 Testing	PD-L1 Result
 Advanced cervical cancer	KEYTRUDA, in combination with chemoradiotherapy (CRT), is indicated for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer.		
	KEYTRUDA, in combination with chemotherapy, with or without bevacizumab, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS $\geq 1$ ) as determined by an FDA-approved test.	✓	CPS $\geq 1$
	KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS $\geq 1$ ) as determined by an FDA-approved test.	✓	CPS $\geq 1$
 Triple-negative breast cancer	KEYTRUDA is indicated for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.		
	KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS $\geq 10$ ) as determined by an FDA-approved test.	✓	CPS $\geq 10$

FIGO = Fédération Internationale de Gynécologie et d'Obstétrique (International Federation of Gynecology and Obstetrics).

## SELECTED SAFETY INFORMATION (*continued*)

### Severe and Fatal Immune-Mediated Adverse Reactions (*continued*)

#### Hepatotoxicity and Immune-Mediated Hepatitis

##### KEYTRUDA as a Single Agent

- KEYTRUDA can cause immune-mediated hepatitis. Immune-mediated hepatitis occurred in 0.7% (19/2799) of patients receiving KEYTRUDA, including Grade 4 (<0.1%), Grade 3 (0.4%), and Grade 2 (0.1%) reactions. Systemic corticosteroids were required in 68% (13/19) of patients; additional immunosuppressant therapy was required in 11% of patients. Hepatitis led to permanent discontinuation of KEYTRUDA in 0.2% (6) and withholding in 0.3% (9) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, none had recurrence. Hepatitis resolved in 79% of the 19 patients.

#### Immune-Mediated Endocrinopathies

##### Adrenal Insufficiency

- KEYTRUDA can cause primary or secondary adrenal insufficiency. For Grade 2 or higher, initiate symptomatic treatment, including hormone replacement as clinically indicated. Withhold KEYTRUDA depending on severity. Adrenal insufficiency occurred in 0.8% (22/2799) of patients receiving KEYTRUDA, including Grade 4 (<0.1%), Grade 3 (0.3%), and Grade 2 (0.3%) reactions. Systemic corticosteroids were required in 77% (17/22) of patients; of these, the majority remained on systemic corticosteroids. Adrenal insufficiency led to permanent discontinuation of KEYTRUDA in <0.1% (1) and withholding in 0.3% (8) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement.


##### Hypophysitis

- KEYTRUDA can cause immune-mediated hypophysitis. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field defects. Hypophysitis can cause hypopituitarism. Initiate hormone replacement as indicated. Withhold or permanently discontinue KEYTRUDA depending on severity. Hypophysitis occurred in 0.6% (17/2799) of patients receiving KEYTRUDA, including Grade 4 (<0.1%), Grade 3 (0.3%), and Grade 2 (0.2%) reactions. Systemic corticosteroids were required in 94% (16/17) of patients; of these, the majority remained on systemic corticosteroids. Hypophysitis led to permanent discontinuation of KEYTRUDA in 0.1% (4) and withholding in 0.3% (7) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement.

Before prescribing KEYTRUDA, please read the additional Selected Safety Information on the previous and following pages, and the [Prescribing Information](#). The [Medication Guide](#) also is available.







**KEYTRUDA**<sup>®</sup>  
(pembrolizumab) Injection 100 mg





# KEYTRUDA Is Approved for a Range of Patients

Slide image is a copyright © of Agilent Technologies, Inc. 2023. Reproduced with Permission, Courtesy of Agilent Technologies, Inc.

Tumor Type	Indication	MSI/MMR Testing	MSI/MMR Result
 Advanced MSI-H/dMMR cancers	KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.		MSI-H or dMMR
 Advanced MSI-H/ dMMR CRC	KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test.		MSI-H or dMMR
 Advanced MSI-H/dMMR endometrial carcinoma	KEYTRUDA, as a single agent, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.		MSI-H or dMMR

MSI = microsatellite instability; MMR = mismatch repair.

## SELECTED SAFETY INFORMATION (continued)

### Severe and Fatal Immune-Mediated Adverse Reactions (continued)

#### Immune-Mediated Endocrinopathies (continued)


##### Thyroid Disorders

- KEYTRUDA can cause immune-mediated thyroid disorders. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism. Initiate hormone replacement for hypothyroidism or institute medical management of hyperthyroidism as clinically indicated. Withhold or permanently discontinue KEYTRUDA depending on severity. Thyroiditis occurred in 0.6% (16/2799) of patients receiving KEYTRUDA, including Grade 2 (0.3%). None discontinued, but KEYTRUDA was withheld in <0.1% (1) of patients.
- Hyperthyroidism occurred in 3.4% (96/2799) of patients receiving KEYTRUDA, including Grade 3 (0.1%) and Grade 2 (0.8%). It led to permanent discontinuation of KEYTRUDA in <0.1% (2) and withholding in 0.3% (7) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement. Hypothyroidism occurred in 8% (237/2799) of patients receiving KEYTRUDA, including Grade 3 (0.1%) and Grade 2 (6.2%). It led to permanent discontinuation of KEYTRUDA in <0.1% (1) and withholding in 0.5% (14) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement. The majority of patients with hypothyroidism required long-term thyroid hormone replacement. The incidence of new or worsening hypothyroidism was higher in 1185 patients with HNSCC, occurring in 16% of patients receiving KEYTRUDA as a single agent or in combination with platinum and FU, including Grade 3 (0.3%) hypothyroidism. The incidence of new or worsening hyperthyroidism was higher in 580 patients with resected NSCLC, occurring in 11% of patients receiving KEYTRUDA as a single agent as adjuvant treatment, including Grade 3 (0.2%) hyperthyroidism. The incidence of new or worsening hypothyroidism was higher in 580 patients with resected NSCLC, occurring in 22% of patients receiving KEYTRUDA as a single agent as adjuvant treatment (KEYNOTE-091), including Grade 3 (0.3%) hypothyroidism.

Before prescribing KEYTRUDA, please read the additional Selected Safety Information on the previous and following pages, and the [Prescribing Information](#). The [Medication Guide](#) also is available.









# KEYTRUDA Is Approved for a Range of Patients

Slide image is a copyright © of Agilent Technologies, Inc. 2023. Reproduced with Permission, Courtesy of Agilent Technologies, Inc.

Tumor Type	Indication	HER2 Testing	HER2 Result
 Advanced gastric or GEJ cancer	KEYTRUDA, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma.		HER2-negative

HER2 = human epidermal growth factor receptor 2.

This resource only covers KEYTRUDA eligibility for select indications with biomarker requirements. Please visit [keytrudahcp.com](https://keytrudahcp.com) for full list of indications.

## SELECTED SAFETY INFORMATION (*continued*)

### Severe and Fatal Immune-Mediated Adverse Reactions (*continued*)

#### Immune-Mediated Endocrinopathies (*continued*)

##### *Type 1 Diabetes Mellitus (DM), Which Can Present With Diabetic Ketoacidosis*

- Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Initiate treatment with insulin as clinically indicated. Withhold KEYTRUDA depending on severity. Type 1 DM occurred in 0.2% (6/2799) of patients receiving KEYTRUDA. It led to permanent discontinuation in <0.1% (1) and withholding of KEYTRUDA in <0.1% (1) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement.

#### Immune-Mediated Nephritis With Renal Dysfunction

- KEYTRUDA can cause immune-mediated nephritis. Immune-mediated nephritis occurred in 0.3% (9/2799) of patients receiving KEYTRUDA, including Grade 4 (<0.1%), Grade 3 (0.1%), and Grade 2 (0.1%) reactions. Systemic corticosteroids were required in 89% (8/9) of patients. Nephritis led to permanent discontinuation of KEYTRUDA in 0.1% (3) and withholding in 0.1% (3) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, none had recurrence. Nephritis resolved in 56% of the 9 patients.

#### Immune-Mediated Dermatologic Adverse Reactions

- KEYTRUDA can cause immune-mediated rash or dermatitis. Exfoliative dermatitis, including Stevens-Johnson syndrome, drug rash with eosinophilia and systemic symptoms, and toxic epidermal necrolysis, has occurred with anti-PD-1/PD-L1 treatments. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate nonexfoliative rashes. Withhold or permanently discontinue KEYTRUDA depending on severity. Immune-mediated dermatologic adverse reactions occurred in 1.4% (38/2799) of patients receiving KEYTRUDA, including Grade 3 (1%) and Grade 2 (0.1%) reactions. Systemic corticosteroids were required in 40% (15/38) of patients. These reactions led to permanent discontinuation in 0.1% (2) and withholding of KEYTRUDA in 0.6% (16) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, 6% had recurrence. The reactions resolved in 79% of the 38 patients.

Before prescribing KEYTRUDA, please read the additional Selected Safety Information on the previous and following pages, and the [Prescribing Information](#). The [Medication Guide](#) also is available.

**KEYTRUDA**<sup>®</sup>  
(pembrolizumab) Injection 100 mg





# KEYTRUDA Is Approved for a Range of Patients

Slide image is a copyright © of Agilent Technologies, Inc. 2023. Reproduced with Permission, Courtesy of Agilent Technologies, Inc.

## SELECTED SAFETY INFORMATION (*continued*)

### Severe and Fatal Immune-Mediated Adverse Reactions (*continued*)

#### Other Immune-Mediated Adverse Reactions

- The following clinically significant immune-mediated adverse reactions occurred at an incidence of <1% (unless otherwise noted) in patients who received KEYTRUDA or were reported with the use of other anti-PD-1/PD-L1 treatments. Severe or fatal cases have been reported for some of these adverse reactions. *Cardiac/Vascular:* Myocarditis, pericarditis, vasculitis; *Nervous System:* Meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barré syndrome, nerve paresis, autoimmune neuropathy; *Ocular:* Uveitis, iritis and other ocular inflammatory toxicities can occur. Some cases can be associated with retinal detachment. Various grades of visual impairment, including blindness, can occur. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada-like syndrome, as this may require treatment with systemic steroids to reduce the risk of permanent vision loss; *Gastrointestinal:* Pancreatitis, to include increases in serum amylase and lipase levels, gastritis, duodenitis; *Musculoskeletal and Connective Tissue:* Myositis/polymyositis, rhabdomyolysis (and associated sequelae, including renal failure), arthritis (1.5%), polymyalgia rheumatica; *Endocrine:* Hypoparathyroidism; *Hematologic/Immune:* Hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, solid organ transplant rejection, other transplant (including corneal graft) rejection.

#### Infusion-Related Reactions

- KEYTRUDA can cause severe or life-threatening infusion-related reactions, including hypersensitivity and anaphylaxis, which have been reported in 0.2% of 2799 patients receiving KEYTRUDA. Monitor for signs and symptoms of infusion-related reactions. Interrupt or slow the rate of infusion for Grade 1 or Grade 2 reactions. For Grade 3 or Grade 4 reactions, stop infusion and permanently discontinue KEYTRUDA.

#### Complications of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

- Fatal and other serious complications can occur in patients who receive allogeneic HSCT before or after anti-PD-1/PD-L1 treatments. Transplant-related complications include hyperacute graft-versus-host disease (GVHD), acute and chronic GVHD, hepatic veno-occlusive disease after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between anti-PD-1/PD-L1 treatments and allogeneic HSCT. Follow patients closely for evidence of these complications and intervene promptly. Consider the benefit vs risks of using anti-PD-1/PD-L1 treatments prior to or after an allogeneic HSCT.

#### Increased Mortality in Patients With Multiple Myeloma

- In trials in patients with multiple myeloma, the addition of KEYTRUDA to a thalidomide analogue plus dexamethasone resulted in increased mortality. Treatment of these patients with an anti-PD-1/PD-L1 treatment in this combination is not recommended outside of controlled trials.

#### Embryofetal Toxicity

- Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman. Advise women of this potential risk. In females of reproductive potential, verify pregnancy status prior to initiating KEYTRUDA and advise them to use effective contraception during treatment and for 4 months after the last dose.


#### Adverse Reactions

- When KEYTRUDA was used as monotherapy, the most common adverse reactions ( $\geq 20\%$ ) were fatigue, musculoskeletal pain, rash, diarrhea, pyrexia, cough, decreased appetite, pruritus, dyspnea, constipation, pain, abdominal pain, nausea, and hypothyroidism.
- When KEYTRUDA was used in combination with chemotherapy or chemoradiotherapy, the most common adverse reactions ( $\geq 20\%$ ) were fatigue/asthenia, nausea, constipation, diarrhea, decreased appetite, rash, vomiting, cough, dyspnea, pyrexia, alopecia, peripheral neuropathy, mucosal inflammation, stomatitis, headache, weight loss, abdominal pain, arthralgia, myalgia, insomnia, palmar-plantar erythrodysesthesia, urinary tract infection, and hypothyroidism.
- When KEYTRUDA was used in combination with chemotherapy and bevacizumab, the most common adverse reactions ( $\geq 20\%$ ) were peripheral neuropathy, alopecia, anemia, fatigue/asthenia, nausea, neutropenia, diarrhea, hypertension, thrombocytopenia, constipation, arthralgia, vomiting, urinary tract infection, rash, leukopenia, hypothyroidism, and decreased appetite.

#### Lactation

- Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment and for 4 months after the last dose.





# A Key to Informing Treatment Decisions for Certain Patients: Biomarker Testing

Slide image is a copyright © of Agilent Technologies, Inc. 2023. Reproduced with Permission, Courtesy of Agilent Technologies, Inc.

CPS and TPS both can evaluate PD-L1 expression in certain cancers and can help identify patients eligible for treatment with KEYTRUDA<sup>1</sup>

CPS <sup>1</sup> HNSCC, gastric or GEJ adenocarcinoma, ESCC, cervical cancer, TNBC	TPS <sup>1</sup> NSCLC
Evaluate the number of PD-L1–staining cells (tumor cells, lymphocytes, macrophages) relative to all viable tumor cells.	Evaluate the percentage of viable tumor cells showing partial or complete membrane staining at any intensity.
$\text{CPS} = \frac{\text{\# of PD-L1–staining cells (tumor cells, lymphocytes, macrophages)}}{\text{Total \# of viable tumor cells}} \times 100$	$\text{TPS (\%)} = \frac{\text{\# of PD-L1–staining cells (tumor cells)}}{\text{Total \# of viable tumor cells}} \times 100$

ESCC = esophageal squamous cell carcinoma.

## MSI-H/dMMR occurs in multiple solid tumor types, including:

<b>GASTROINTESTINAL CANCERS</b> Colorectal, biliary, gastric or GEJ, pancreatic, small intestinal, appendiceal adenocarcinoma, <sup>a</sup> abdominal adenocarcinoma	<b>GYNECOLOGIC AND BREAST CANCERS</b> Endometrial, ovarian, cervical, vaginal, vulvar, breast
<b>GENITOURINARY CANCERS</b> Prostate, bladder, renal cell, testicular	<b>OTHER CANCERS</b> Sarcoma, thyroid, retroperitoneal, small cell lung, brain, neuroendocrine, adrenocortical, mesothelioma, salivary, anal, HNSCC, nasopharyngeal, hepatocellular carcinoma, carcinoma of unknown origin

<sup>a</sup>Not otherwise specified.

## SELECTED SAFETY INFORMATION (*continued*)

### Pediatric Use

- In KEYNOTE-051, 173 pediatric patients (65 pediatric patients aged 6 months to younger than 12 years and 108 pediatric patients aged 12 years to 17 years) were administered KEYTRUDA 2 mg/kg every 3 weeks. The median duration of exposure was 2.1 months (range: 1 day to 25 months).
- Adverse reactions that occurred at a ≥10% higher rate in pediatric patients when compared to adults were pyrexia (33%), leukopenia (30%), vomiting (29%), neutropenia (28%), headache (25%), abdominal pain (23%), thrombocytopenia (22%), Grade 3 anemia (17%), decreased lymphocyte count (13%), and decreased white blood cell count (11%).

Before prescribing KEYTRUDA, please read the Selected Safety Information on the previous pages and the [Prescribing Information](#). The [Medication Guide](#) also is available.

Reference: 1. Agilent Technologies, Inc. Instructions for Use: PD-L1 IHC 22C3 pharmDx.

